Medical research

New therapeutic approaches for SARS-CoV-2

Medicine has two things to offer when viral pandemics hit: vaccines and therapeutics. While it is hard to undervalue the noble goal of rapidly developing and rolling out safe vaccines that effectively reduce disease severity, ...

Diseases, Conditions, Syndromes

Study discloses new test for river blindness infection

Scientists at The Scripps Research Institute (TSRI) have found a telltale molecular marker for Onchocerciasis or "river blindness," a parasitic infection that affects tens of millions of people in Africa, Latin America and ...

Diseases, Conditions, Syndromes

Study finds no benefit to taking ivermectin for COVID-19 symptoms

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants ...

Medications

Early ivermectin does not reduce hospital admission in COVID-19

Early ivermectin treatment does not reduce the risk for hospital admission or prolonged emergency department observation visits for adults with symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, ...

page 1 from 6

Ivermectin

Ivermectin (22,23-dihydroavermectin B1a + 22,23-dihydroavermectin B1b) is a broad-spectrum antiparasitic avermectin medicine.

It is sold under brand names Stromectol in the United States, Ivomec in Europe by Merial Animal Health, Mectizan in Canada by Merck and Ivexterm in Mexico by Valeant Pharmaceuticals International. While in development, it was assigned the code MK-933 by Merck.

This text uses material from Wikipedia, licensed under CC BY-SA